GSK wins ap­peal to on­ly pay As­traZeneca roy­al­ties on some sales of can­cer drug Ze­ju­la

A pan­el of judges on the UK civ­il court of ap­peals agreed that GSK sub­sidiary Tesaro doesn’t have to pay roy­al­ties to As­traZeneca on to­tal sales of its ovar­i­an can­cer drug Ze­ju­la, over­turn­ing a pre­vi­ous rul­ing from 2023.

The new rul­ing means that GSK on­ly has to pay roy­al­ties on a sub­set of Ze­ju­la sales, which is a com­mer­cial­ly pos­i­tive turn for the com­pa­ny. The spe­cif­ic amount, how­ev­er, has yet to be de­cid­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER